355 related articles for article (PubMed ID: 30006485)
1. D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.
Zhang L; Sorensen MD; Kristensen BW; Reifenberger G; McIntyre TM; Lin F
Clin Cancer Res; 2018 Nov; 24(21):5381-5391. PubMed ID: 30006485
[No Abstract] [Full Text] [Related]
2. Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma.
Dettling S; Stamova S; Warta R; Schnölzer M; Rapp C; Rathinasamy A; Reuss D; Pocha K; Roesch S; Jungk C; Warnken U; Eckstein V; Grabe N; Schramm C; Weigand MA; von Deimling A; Unterberg A; Beckhove P; Herold-Mende C
Clin Cancer Res; 2018 Jun; 24(12):2951-2962. PubMed ID: 29563135
[No Abstract] [Full Text] [Related]
3. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
4. Tissue 2-Hydroxyglutarate as a Biomarker for
Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX
Clin Cancer Res; 2019 Jun; 25(11):3366-3373. PubMed ID: 30777876
[TBL] [Abstract][Full Text] [Related]
5. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
[TBL] [Abstract][Full Text] [Related]
7. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Fathi AT; Nahed BV; Wander SA; Iafrate AJ; Borger DR; Hu R; Thabet A; Cahill DP; Perry AM; Joseph CP; Muzikansky A; Chi AS
Oncologist; 2016 Feb; 21(2):214-9. PubMed ID: 26834160
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
[TBL] [Abstract][Full Text] [Related]
9. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
Yan D; Li W; Liu Q; Yang K
Front Immunol; 2022; 13():914618. PubMed ID: 35769466
[TBL] [Abstract][Full Text] [Related]
10. 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
Wahl DR; Venneti S
Brain Pathol; 2015 Nov; 25(6):760-8. PubMed ID: 26526944
[TBL] [Abstract][Full Text] [Related]
11. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Friedrich M; Hahn M; Michel J; Sankowski R; Kilian M; Kehl N; Günter M; Bunse T; Pusch S; von Deimling A; Wick W; Autenrieth SE; Prinz M; Platten M; Bunse L
Neuro Oncol; 2023 Feb; 25(2):263-276. PubMed ID: 35609569
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
13. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Bunse L; Pusch S; Bunse T; Sahm F; Sanghvi K; Friedrich M; Alansary D; Sonner JK; Green E; Deumelandt K; Kilian M; Neftel C; Uhlig S; Kessler T; von Landenberg A; Berghoff AS; Marsh K; Steadman M; Zhu D; Nicolay B; Wiestler B; Breckwoldt MO; Al-Ali R; Karcher-Bausch S; Bozza M; Oezen I; Kramer M; Meyer J; Habel A; Eisel J; Poschet G; Weller M; Preusser M; Nadji-Ohl M; Thon N; Burger MC; Harter PN; Ratliff M; Harbottle R; Benner A; Schrimpf D; Okun J; Herold-Mende C; Turcan S; Kaulfuss S; Hess-Stumpp H; Bieback K; Cahill DP; Plate KH; Hänggi D; Dorsch M; Suvà ML; Niemeyer BA; von Deimling A; Wick W; Platten M
Nat Med; 2018 Aug; 24(8):1192-1203. PubMed ID: 29988124
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of 2-hydroxyglutarate as a controversial oncometabolite in malignant gliomas.
Bystricky P; Kasubova I; Richterova R; Lasabova Z; Kolarovszki B
Neoplasma; 2020 Nov; 67(6):1367-1372. PubMed ID: 32853017
[TBL] [Abstract][Full Text] [Related]
15. D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.
Cao C; Zhang L; Sorensen MD; Reifenberger G; Kristensen BW; McIntyre TM; Lin F
J Neuropathol Exp Neurol; 2023 Oct; 82(11):921-933. PubMed ID: 37740942
[TBL] [Abstract][Full Text] [Related]
16. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract][Full Text] [Related]
17. Local and systemic effects of IDH mutations on primary glioma patients.
Tang F; Wang DW; Xi C; Yang JZ; Liu ZY; Yu DH; Wang ZF; Li ZQ
Immunology; 2023 Aug; 169(4):503-514. PubMed ID: 37054988
[TBL] [Abstract][Full Text] [Related]
18. Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas.
Pichumani K; Mashimo T; Baek HM; Ratnakar J; Mickey B; DeBerardinis RJ; Maher EA; Bachoo RM; Malloy CR; Kovacs Z
Anal Biochem; 2015 Jul; 481():4-6. PubMed ID: 25908561
[TBL] [Abstract][Full Text] [Related]
19. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.
Oizel K; Gratas C; Nadaradjane A; Oliver L; Vallette FM; Pecqueur C
Cell Death Dis; 2015 Mar; 6(3):e1704. PubMed ID: 25811801
[TBL] [Abstract][Full Text] [Related]
20. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]